These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 7847868

  • 1. Plasticity of nerve afferents to nigrostriatal neurons in Parkinson's disease.
    Anglade P, Tsuji S, Javoy-Agid F, Agid Y, Hirsch EC.
    Ann Neurol; 1995 Feb; 37(2):265-72. PubMed ID: 7847868
    [Abstract] [Full Text] [Related]

  • 2. Nigrostriatal system plasticity in Parkinson's disease: effect of dopaminergic denervation and treatment.
    Hirsch EC.
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S115-20; discussion S120-1. PubMed ID: 10762138
    [Abstract] [Full Text] [Related]

  • 3. Ultrastructural relations between nigrostriatal dopaminergic neurons and cholinergic nerve endings in the human brain.
    Anglade P, Tsuji S, Hirsch EC, Javoy-Agid F, Agid Y.
    Histol Histopathol; 1993 Jul; 8(3):501-4. PubMed ID: 8102915
    [Abstract] [Full Text] [Related]

  • 4. Synaptic reorganisation in the rat striatum after dopaminergic deafferentation: an ultrastructural study using glutamate decarboxylase immunocytochemistry.
    Nitsch C, Riesenberg R.
    Synapse; 1995 Apr; 19(4):247-63. PubMed ID: 7792720
    [Abstract] [Full Text] [Related]

  • 5. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.
    Huot P, Lévesque M, Parent A.
    Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832
    [Abstract] [Full Text] [Related]

  • 6. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.
    Prescott IA, Dostrovsky JO, Moro E, Hodaie M, Lozano AM, Hutchison WD.
    Brain; 2009 Feb; 132(Pt 2):309-18. PubMed ID: 19050033
    [Abstract] [Full Text] [Related]

  • 7. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L, Garris BL, Garris DR, Lau YS.
    Neuroscience; 2006 Jun 19; 140(1):67-76. PubMed ID: 16533572
    [Abstract] [Full Text] [Related]

  • 8. Striatal susceptibility to a dopaminergic neurotoxin is independent of sex hormone effects on cell survival and DAT expression but is exacerbated by central aromatase inhibition.
    McArthur S, Murray HE, Dhankot A, Dexter DT, Gillies GE.
    J Neurochem; 2007 Feb 19; 100(3):678-92. PubMed ID: 17116232
    [Abstract] [Full Text] [Related]

  • 9. Brain neurotransmitters and neuropeptides in Parkinson's disease.
    Rinne UK, Rinne JO, Rinne JK, Laakso K, Lönnberg P.
    Acta Physiol Pharmacol Latinoam; 1984 Feb 19; 34(3):287-99. PubMed ID: 6099688
    [Abstract] [Full Text] [Related]

  • 10. Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons.
    Porritt MJ, Batchelor PE, Howells DW.
    Exp Neurol; 2005 Mar 19; 192(1):226-34. PubMed ID: 15698637
    [Abstract] [Full Text] [Related]

  • 11. The nigrostriatal system in Parkinson's disease.
    Graybiel AM, Hirsch EC, Agid Y.
    Adv Neurol; 1990 Mar 19; 53():17-29. PubMed ID: 1978514
    [Abstract] [Full Text] [Related]

  • 12. The intrastriatal injection of thrombin in rat induced a retrograde apoptotic degeneration of nigral dopaminergic neurons through synaptic elimination.
    Herrera AJ, de Pablos RM, Carreño-Müller E, Villarán RF, Venero JL, Tomás-Camardiel M, Cano J, Machado A.
    J Neurochem; 2008 May 19; 105(3):750-62. PubMed ID: 18179476
    [Abstract] [Full Text] [Related]

  • 13. Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections.
    Kozlowski DA, Connor B, Tillerson JL, Schallert T, Bohn MC.
    Exp Neurol; 2000 Nov 19; 166(1):1-15. PubMed ID: 11031079
    [Abstract] [Full Text] [Related]

  • 14. p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the parkinsonian brain.
    Mogi M, Kondo T, Mizuno Y, Nagatsu T.
    Neurosci Lett; 2007 Feb 27; 414(1):94-7. PubMed ID: 17196747
    [Abstract] [Full Text] [Related]

  • 15. Identification and kainic acid-induced up-regulation of low-affinity p75 neurotrophin receptor (p75NTR) in the nigral dopamine neurons of adult rats.
    Wang YQ, Bian GL, Bai Y, Cao R, Chen LW.
    Neurochem Int; 2008 Sep 27; 53(3-4):56-62. PubMed ID: 18639597
    [Abstract] [Full Text] [Related]

  • 16. Nerve growth factor increases survival of dopaminergic graft, rescue nigral dopaminergic neurons and restores functional deficits in rat model of Parkinson's disease.
    Chaturvedi RK, Shukla S, Seth K, Agrawal AK.
    Neurosci Lett; 2006 May 01; 398(1-2):44-9. PubMed ID: 16423459
    [Abstract] [Full Text] [Related]

  • 17. Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat.
    Connor B, Kozlowski DA, Schallert T, Tillerson JL, Davidson BL, Bohn MC.
    Gene Ther; 1999 Dec 01; 6(12):1936-51. PubMed ID: 10637445
    [Abstract] [Full Text] [Related]

  • 18. Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease.
    Calabresi P, Mercuri NB, Sancesario G, Bernardi G.
    Brain; 1993 Apr 01; 116 ( Pt 2)():433-52. PubMed ID: 8096420
    [Abstract] [Full Text] [Related]

  • 19. [The life history of brain dopamine].
    Hornykiewicz O.
    Wien Klin Wochenschr; 1985 Apr 12; 97(8):350-4. PubMed ID: 2986364
    [Abstract] [Full Text] [Related]

  • 20. Regulation of GAP-43 protein and mRNA in nigrostriatal dopaminergic neurons after the partial destruction of dopaminergic terminals with intrastriatal 6-hydroxydopamine.
    Iwata SI, Nomoto M, Fukuda T.
    Synapse; 2001 Jan 12; 39(1):16-22. PubMed ID: 11071705
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.